Patents by Inventor Ewa Budzynski

Ewa Budzynski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING A RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR WITH AN EXPRESSION CASSETTE ENCODING A TRANSGENE FOR SUPRACHOROIDAL ADMINISTRATION
    Publication number: 20260034243
    Abstract: Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.
    Type: Application
    Filed: April 5, 2023
    Publication date: February 5, 2026
    Inventors: Jared Bee, Tristan James Marshall, Sherri Van Everen, Stephen Joseph Pakola, Nicholas Alexander Piers Sascha Buss, Anthony Ray O'Berry, Jesse I. Yoo, Ewa Budzynski
  • FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS FORMULATIONS WITH AGGREGATE FORMATION
    Publication number: 20250339555
    Abstract: Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.
    Type: Application
    Filed: April 5, 2023
    Publication date: November 6, 2025
    Inventors: Jared BEE, Tristan James MARSHALL, Sherri VAN EVEREN, Stephen Joseph PAKOLA, Ewa BUDZYNSKI, Nicholas Alexander Piers Sasha BUSS
  • VECTORIZED ANTI-TNF-ALPHA INHIBITORS FOR OCULAR INDICATIONS
    Publication number: 20250288697
    Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified therapeutic monoclonal antibody, or an antigen binding fragment thereof, that binds to TNF-a, to a human subject for treatment of an ocular indication, particularly non-infectious uveitis. The nucleotide sequence encoding the antibody is delivered in a rAAV vector that targets ocular tissue cells for expression of the transgene.
    Type: Application
    Filed: May 3, 2023
    Publication date: September 18, 2025
    Inventors: Joseph Bruder, Xu Wang, Devin McDougald, Ye Liu, Olivier Danos, Wei-Hua Lee, Chunping Qiao, Ewa Budzynski, Mikayla Higgins, Mi Shi, Jessica Gumerson
  • FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS HIGH VISCOSITY FORMULATIONS
    Publication number: 20240024508
    Abstract: Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.
    Type: Application
    Filed: October 6, 2021
    Publication date: January 25, 2024
    Inventors: Jared Bee, Tristan James Marshall, Sherri Van Everen, Stephen Joseph Pakola, Nicholas Alexander Piers Sascha Buss, Anthony Ray O'Berry, Jesse I. Yoo, Ewa Budzynski
  • FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS GEL FORMULATIONS
    Publication number: 20230414788
    Abstract: Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.
    Type: Application
    Filed: October 6, 2021
    Publication date: December 28, 2023
    Inventors: Jared Bee, Tristan James Marshall, Sherri Van Everen, Stephen Joseph Pakola, Nicholas Alexander Piers Sascha Buss, Anthony Ray O'Berry, Jesse I. Yoo, Ewa Budzynski
  • VECTORIZED ANTI-TNF-ALPHA ANTIBODIES FOR OCULAR INDICATIONS
    Publication number: 20230391864
    Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified therapeutic monoclonal antibody, or an antigen binding fragment thereof, that binds to TNF-?, IL6 or IL6-R to a human subject for treatment of an ocular indication, particularly non-infectious uveitis. The nucleotide sequence encoding the antibody is delivered in a rAAV vector that targets ocular tissue cells for expression of the transgene.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 7, 2023
    Inventors: Xu Wang, Devin McDougald, Joseph Bruder, Ye Liu, Olivier Danos, Wei-Hua Lee, Chunping Qiao, Ewa Budzynski, Mikayla Higgins, Mi Shi
  • FORMULATIONS FOR SUPRACHOROIDAL ADMINISTRATION SUCH AS FORMULATIONS WITH AGGREGATE FORMATION
    Publication number: 20230372538
    Abstract: Provided herein are pharmaceutical compositions for administration to a suprachoroidal space of an eye of a subject. The pharmaceutical compositions can include a recombinant adeno-associated virus (AAV) encoding a transgene. Also provided herein are methods for treating or preventing a disease in a subject by administering a therapeutically effective amount of the pharmaceutical compositions to the subject in need.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 23, 2023
    Inventors: Jared Bee, Tristan James Marshall, Sherri Van Everen, Stephen Joseph Pakola, Ewa Budzynski